Get Your Personalized Supplement StackSupplement Stack Quiz

B3

Also known as: Niacin, nicotinic acid, vitamin B3

Overview

Niacin, also known as nicotinic acid or vitamin B3, is an essential water-soluble B-vitamin. It is naturally present in various foods such as meat, fish, nuts, and grains, and is also widely available as a dietary supplement. Niacin plays a crucial role in cellular metabolism and mitochondrial function, acting as a precursor to the coenzymes NAD and NADP. Its primary application in supplement form is to manage dyslipidemia by favorably modifying lipid profiles, specifically by increasing high-density lipoprotein (HDL) cholesterol and reducing low-density lipoprotein (LDL) cholesterol and triglycerides. Beyond lipid management, niacin has been investigated for its potential to reduce cardiovascular disease (CVD) risk and its role in ocular health, particularly in conditions like glaucoma. Research on niacin is extensive, with numerous randomized controlled trials, systematic reviews, and meta-analyses providing high-quality evidence regarding its effects, although some heterogeneity exists in the literature.

Benefits

Niacin offers several evidence-based benefits, primarily in lipid modification and vascular health. It significantly increases apolipoprotein A1 (apo A1) and decreases apolipoprotein B (apo B) levels, key regulators of lipoprotein metabolism. A meta-analysis indicated that short-term niacin intervention reduces apo B, and extended-release niacin (ERN) at higher doses significantly increases apo A1, though heterogeneity limits generalizability. Niacin also improves endothelial function, measured by brachial artery flow-mediated dilation (FMD). Doses of 2000 mg/day or more have been shown to improve FMD by approximately 4.4%, with greater effects observed in patients with coronary artery disease (CAD). While niacin effectively increases HDL cholesterol and reduces LDL cholesterol and triglycerides, its direct impact on reducing cardiovascular events remains less clear. Patients with dyslipidemia, CAD, or acute coronary syndrome tend to show more pronounced benefits in endothelial function and lipid profile improvements. Additionally, lower niacin intake has been observed in patients with glaucoma, suggesting a potential neuroprotective role through mitochondrial support and reduction of oxidative stress, although clinical outcome data in this area are limited and require further research.

How it works

Niacin functions as a precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital coenzymes involved in numerous redox reactions and energy metabolism within cells. In terms of lipid metabolism, niacin modulates pathways in the liver by reducing the hepatic synthesis of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), while simultaneously increasing high-density lipoprotein (HDL) levels, primarily via apolipoprotein A1 (apo A1). It also improves endothelial function through nitric oxide-mediated vasodilation. The GPR109A receptor (hydroxycarboxylic acid receptor 2) is a key molecular target that mediates both niacin’s lipid-modifying effects and its characteristic flushing side effect. Niacin is well absorbed orally, and extended-release formulations are designed to modify its pharmacokinetics to minimize side effects.

Side effects

While generally safe at recommended doses, higher doses of niacin (typically above 1000 mg/day) can lead to various side effects. The most common adverse effects, affecting over 5% of users, include flushing, itching, and gastrointestinal discomfort. Flushing, characterized by redness, warmth, and tingling of the skin, is mediated by the GPR109A receptor and can be significant, though it often diminishes with continued use or with extended-release formulations. Uncommon side effects, occurring in 1-5% of individuals, include hepatotoxicity (liver damage), hyperuricemia (elevated uric acid levels, potentially leading to gout), and glucose intolerance (elevated blood sugar). Rare but serious side effects, affecting less than 1% of users, include severe liver injury and rhabdomyolysis (muscle breakdown), particularly when niacin is combined with statins. Niacin can interact with other medications; it may increase the risk of muscle toxicity when taken with statins and requires caution with diabetes medications due to its potential to elevate blood glucose. Contraindications for niacin use include active liver disease, severe gout, and peptic ulcer disease. Special consideration is needed for diabetic patients, who should use niacin cautiously, and liver function should be monitored, especially at higher doses.

Dosage

For lipid modification and improvement in endothelial function, a dosage range of 1000–2000 mg/day is generally considered optimal. Lipid effects can be observed at doses as low as 500 mg/day. The maximum safe dose is typically up to 2000 mg/day, as higher doses significantly increase the risk of adverse effects. To minimize common side effects like flushing, extended-release formulations are preferred for lipid management. Niacin should ideally be taken with meals, as food enhances absorption and can help reduce gastrointestinal discomfort. Gradual dose escalation is often recommended to improve tolerance to flushing. While no specific cofactors are required for niacin absorption or efficacy, monitoring of liver enzymes is advised, especially when using higher doses, to ensure safety.

FAQs

Is niacin safe for long-term use?

Long-term use of niacin, especially at high doses, requires careful monitoring for potential side effects such as liver toxicity and glucose intolerance.

When should niacin be taken?

Niacin is best taken with meals to improve tolerance and absorption. Extended-release forms are often recommended to minimize flushing.

How soon will benefits appear?

Changes in lipid profiles can be observed within weeks of starting niacin. Improvements in endothelial function may take longer, often several weeks to months.

Does niacin reduce cardiovascular events?

While niacin improves lipid profiles, evidence regarding its ability to directly reduce cardiovascular events is inconsistent and limited in clinical trials.

Is flushing a sign of overdose?

Flushing is a very common side effect of niacin, not necessarily an overdose. It can be managed by starting with low doses, gradual escalation, or using extended-release formulations.

Research Sources

https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effects-of-niacin-on-apo-a1-and-b-levels-a-systematic-review-and-metaanalysis-of-randomised-controlled-trials/4AA60603C1BA78A6D57067458421F780 – This systematic review and meta-analysis investigated the effects of niacin on apolipoprotein A1 (apo A1) and apolipoprotein B (apo B) levels. It found that niacin significantly reduced apo B and increased apo A1, key regulators of lipoprotein metabolism. However, the study noted substantial heterogeneity and a high risk of bias among the included randomized controlled trials, suggesting a need for further well-designed research.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2730481 – This systematic review and meta-analysis evaluated the impact of niacin on cardiovascular outcomes. It reviewed 119 clinical trials, including 17 with cardiovascular disease (CVD) outcomes, and concluded that while niacin increased HDL-C, the evidence for its ability to reduce CVD events was inconclusive. The study highlighted that many trials relied on surrogate endpoints rather than hard clinical outcomes.
https://journals.sagepub.com/doi/full/10.1177/1358863x13515766 – This meta-analysis focused on niacin's effect on endothelial function, specifically assessing brachial artery flow-mediated dilation (FMD). It found a dose-dependent improvement in endothelial function, particularly with doses of 2000 mg/day or more. The study was considered high quality with robust sensitivity analyses, supporting niacin's role in vascular health.
https://pubmed.ncbi.nlm.nih.gov/39519437/ – This systematic review explored the relationship between niacin intake and glaucoma. It identified observational studies (case-control and cohort) showing lower niacin intake in patients with glaucoma. The review suggests a potential neuroprotective role for niacin through mitochondrial support, but emphasizes that these are observational findings requiring confirmation from randomized controlled trials.